Analytical Data
-
基因名
DPAGT1
- Application
-
别名
DPAGT1；DPAGT2；UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9H3H5
-
表达区间
1-408aa
-
氨基酸序列
MWAFSELPMPLLINLIVSLLGFVATVTLIPAFRGHFIAARLCGQDLNKTSRQQIPESQGVISGAVFLIILFCFIPFPFLNCFVKEQCKAFPHHEFVALIGALLAICCMIFLGFADDVLNLRWRHKLLLPTAASLPLLMVYFTNFGNTTIVVPKPFRPILGLHLDLGILYYVYMGLLAVFCTNAINILAGINGLEAGQSLVISASIIVFNLVELEGDCRDDHVFSLYFMIPFFFTTLGLLYHNWYPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVFNFLYSLPQLLHIIPCPRHRIPRLNIKTGKLEMSYSKFKTKSLSFLGTFILKVAESLQLVTVHQSETEDGEFTECNNMTLINLLLKVLGPIHERNLTLLLLLLQILGSAITFSIRYQLVRLFYDV
-
分子量
46 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DPAGT1 (Dolichyl-Phosphate N-Acetylglucosamine Phosphotransferase 1) is a crucial enzyme involved in the initial steps of N-glycosylation, a vital post-translational modification that influences protein folding, stability, and cell signaling. Mutations in the DPAGT1 gene can lead to a rare genetic disorder known as congenital disorder of glycosylation type IIb (CDG-IIb), characterized by neurodevelopmental defects, impaired glycoprotein synthesis, and various clinical manifestations. Given the significance of DPAGT1 in maintaining cellular homeostasis and the pathological consequences of its dysfunction, the study of recombinant DPAGT1 protein has garnered attention to elucidate its structure, function, and the molecular mechanisms underlying its enzymatic activity. Research involving recombinant DPAGT1 aims to enhance our understanding of its role in glycoprotein biosynthesis and offers potential therapeutic avenues for treating associated disorders. By expressing DPAGT1 in heterologous systems, scientists can investigate the enzyme's catalytic properties, identify substrates, and assess how mutations impact its function. This knowledge is essential for developing targeted treatments or biotherapeutics for patients with CDG-IIb, paving the way for innovative intervention strategies and improving patient outcomes.
